Physician profile
Ram Chillar
NPI 1881702645
$2,394.57
in general payments reported to CMS, 2019-2025
37 companies · $294 in 2025
The $294 reported for 2025 was less than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,280 · 2020: $216 · 2021: $31.20 · 2022: $99.95 · 2023: $134 · 2024: $340 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $552 · Education: $216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $551.91 |
| Education | $215.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $214.29 | 2022-2024 | Padcev |
| Janssen Biotech, INC. | $200.92 | 2019-2024 | Imbruvica, Darzalex, Carvykti |
| Novartis Pharmaceuticals Corporation | $189.14 | 2019-2025 | |
| Lilly USA, LLC | $167.98 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $165.36 | 2019-2024 | Keytruda |
| Sobi, INC | $151.05 | 2023-2025 | |
| Pfizer INC. | $131.28 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $129.05 | 2019 | |
| Kite Pharma, INC. | $127.50 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $97.25 | 2019-2025 | Enhertu, Imfinzi |
| Amgen INC. | $69.81 | 2019 | |
| Rigel Pharmaceuticals, INC. | $62.04 | 2019-2025 | Gavreto, Rezlidhia, Tavalisse |
| Abbvie INC. | $61.34 | 2023-2024 | Venclexta |
| Taiho Oncology, INC. | $53.53 | 2019-2025 | |
| Puma Biotechnology, INC. | $51.87 | 2019 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $47.33 | 2019 | |
| Genzyme Corporation | $46.56 | 2019 | |
| Gilead Sciences, INC. | $36.63 | 2019 | |
| Daiichi Sankyo INC. | $30.80 | 2019 | |
| Amneal Pharmaceuticals LLC | $28.02 | 2024 | Neulasta, Avastin, Neupogen |
| Springworks Therapeutics, INC. | $26.94 | 2024 | Ogsiveo |
| Octapharma USA, INC. | $26.75 | 2019 | |
| Tersera Therapeutics LLC | $25.38 | 2023 | Zoladex |
| Emd Serono, INC. | $23.99 | 2019 | |
| Caris Mpi, INC. | $22.51 | 2025 | Mi Cancer Seek |
| Takeda Pharmaceuticals U.S.A., INC. | $22.16 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.78 | 2025 | |
| Tesaro, INC. | $19.70 | 2019 | |
| Aurobindo Pharma USA, INC. | $19.69 | 2020 | |
| Argenx US, INC. | $19.53 | 2024 | Vyvgart Hytrulo, Vyvgart |
| Medtronic USA, INC. | $16.58 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $16.50 | 2019 | |
| Eisai INC. | $15.44 | 2025 | |
| Genentech USA, INC. | $14.31 | 2019 | |
| Celgene Corporation | $14.24 | 2019 | |
| Exelixis INC. | $13.84 | 2019 | |
| Kyowa Kirin, INC. | $13.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ram Chillar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.